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trial). Am J Cardiol 2007;100:1099–102.
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e would like to thank Dr. Denardo for his interest in our work
1), and we appreciate his quoting a proverb that well depicts our
aper’s take-home message. The CIAO (Coronary Interventions
ntiplatelet-based Only) trial is a first step on a journey into
xclusive dual antiplatelet therapy (aspirin and thienopyridine)
lone during percutaneous coronary intervention (PCI), without
cheduled antithrombin or glycoprotein inhibitor therapy.
We disagree with the accompanying editorial (2), which states
hat dual antiplatelet therapy alone may lack an essential “safety
et” that could be provided by antithrombin therapy or, perhaps,
lycoprotein inhibitor therapy. As pointed out by Dr. Denardo,
he use of aspirin, combined with adequate patient pretreatment
ith a thienopyridine, will guarantee an adequate inhibition of
latelet activity and lack of triggering for the coagulation cascade
uring a planned PCI (3,4).
Moreover, the use of the glycoprotein IIb/IIIa inhibitors (e.g.,
bciximab) will not add a further inhibition of the the final
ommon pathway of platelet aggregation in stable patients in
hronic treatment with thienopiridine. Solid clinical data proving
he opposite are still lacking.
So far, the the only proof of this theory is the absence of
hrombotic occlusions and the lower ischemic complications dur-
ng PCI (i.e., periprocedural myocardial damage) in the placebo
roup of the CIAO trial (1).
An additional point is related to procedural costs. Our approach
s aimed at a safe and efficient removal of expensive, unnecessary
rugs from elective procedures. This is valid, both for inhibitors of
he anticoagulation cascade, and for glycoprotein IIb/IIIa receptor
nhibitors. We truly believe that these drugs, in this clinical setting,
an only increase the incidence of bleeding and raise the costs
ithout improving the patient’s outcome.
However, as pointed out by Dr. Denardo, further trials are
eeded to make a second step along this path. Testing our
ypothesis for the treatment of more complicated lesions is crucial
o prove the clinical value of CIAO findings.
Finally, we want to thank Dr. Denardo, who has inspired our
ork. Thanks to his pioneering experience, together with the
esults of the REMOVE (Reduction in Major and Minor Adverse
vents With Eptifibatide-based Pharmacotherapy in Percutaneous
oronary Intervention) (5) and CIAO (1) trials, exclusive anti-
latelet therapy is not considered heretical any more.
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Well some things you can explain away,
but the heartache’s in me till this day.
—The Clash, 1979 (1)
read with interest Dr. Denardo’s letter concerning the CIAO
Coronary Interventions Antiplatelet-based Only) trial (2) and the
ccompanying editorial (3). My congratulations are extended to
r. Denardo and other investigators who have found novel
pproaches to reducing bleeding complications associated with
ercutaneous coronary intervention (PCI), including the CIAO
pproach, fondaparinux, bivalirudin, reduced doses of unfraction-
ted heparin, improved femoral access technique, or radial artery
pproaches. As discussed in the editorial (3), caution is warranted
hen data are limited to selected lower-risk patient subsets.
Dr. Denardo’s letter, though, focuses congratulations on the
IAO trial as a “first step on a journey into exclusive dual antiplatelet
herapy.” As expressed in the editorial, there are pathophysiologic
oncerns about embarking on this journey in higher-risk subgroups of
atients. Specifically, concern arises with the statement: “if adequate
ntiplatelet therapy is provided, thrombosis will not occur, even in
he absence of antithrombin therapy. . . .” Arguments against
his hypothesis are the following:
During the REMOVE (Reduction in Major and Minor Ad-
verse Events With Eptifibatide-based Pharmacotherapy in Per-
cutaneous Coronary Intervention) trial, thrombus did form
during bifurcation PCI despite aspirin, clopidogrel, and glyco-
protein inhibition (GPI). Thus, the protocol was amended to
exclude these higher-risk lesions from a no-antithrombin ap-
proach (4).
Platelet activation is induced by vessel injury, exposure to
collagen, and a myriad of other agents. No antiplatelet agent
that is clinically available can inhibit all pathways of platelet
activation (5). Further, although GPI decreases platelet aggre-
gation and the quantity of platelets in a growing thrombus, it
may not prevent platelet adherence or platelet–leukocyte aggre-
gation that can contribute to thrombin formation (6).
Nonplatelet blood elements, particularly monocytes, support
thrombin generation (7). The exclusive antiplatelet therapy
approach would not necessarily prevent nonplatelet-mediated
generation of thrombin.
